Resumen Según la OMS la forma más eficaz para reducir los casos de rabia anuales en humanos es a través de vacunaciones en perros y gatos, dado que el 90 % de los mismos son debido a mordeduras de estos animales, mayoritariamente caninos, infectados con el virus. En países de la región, donde se ha evaluado el nivel de protección de perros vacunados contra el virus de la rabia, se han encontrado variaciones importantes. El objetivo de este trabajo fue evaluar la respuesta inmune humoral contra la rabia en perros con algún tipo de “modulación inmunológica” inducida experimentalmente. Para esto se inmunizaron cinco grupos de perros con vacunas polivalentes (Grupo 1), monovalentes (Grupo 2), inmunizados durante la castración quirúrgica (Grupo 3), que estaban en tratamiento con Triamcinolona acetonido (corticoides) durante la inmunización (Grupo 4) o que fueron vacunados simultáneamente con un inmunoestimulante comercial (Grupo 5). En términos generales los resultados obtenidos indican que en todos los casos, la mayoría de los animales pudieron superar el límite mínimo de anticuerpos para estar protegidos según la OMS (0.5UI/ml). Sin embargo, se encontraron diferencias significativas (p<0.05) en el uso de vacunas mono o polivalente, el uso de corticoides al momento de la inmunización y en la vacunación durante la castración quirúrgica

Abstract According to WHO the most effective way to reduce the incidence of annual human rabies, is through vaccination of dogs and cats, since 90% of human cases are due to bites mainly from canines infected with the virus. The level of protection of dogs vaccinated against rabies varies significantly between countries of the region. The objective of this study was to evaluate the humoral immune response against rabies, in dogs with some kind of "immune modulation" experimentally induced. Dogs were immunized with polyvalent (Group 1), monovalent (Group 2) vaccines, and immunized during surgical castration (Group 3), dogs treated with triamcinolone acetonide (steroids) during immunization (Group 4) or vaccinated simultaneously with a commercial immunostimulant (Group 5). The results indicate that in all cases, the majority of animals could exceed the minimum limit of antibodies to be protected according to the WHO (0.5UI / ml). However, significant differences (p <0.05) in the use of mono- or polyvalent vaccines, the use of corticosteroids at the time of immunization and vaccination during surgical castration was found

Canine parvovirus type 2 (CPV-2) is a leading cause of diarrhea in puppies in several parts of the world. In this study CPV-2 was detected and recovered from puppies showing clinical disease from Montevideo, Uruguay. Samples were processed and used to infect CRFK and MDCK cells in order to isolate the virus. Out of twelve, two samples were positive for CPV-2. A genomic region of 583 bp was amplified and the molecular characterization was performed by sequencing, phylogenetic analysis and Restriction Fragment Length Polymorphism (RFLP). Two isolated viruses (UY1 and UY2) were CPV-2c-like viruses. The comparison between the cytophatic effect (CPE) of CPV-2 (vaccinal virus) and CPV-2c (isolated virus) on primary canine cells cultures and on CRFK line cells, demonstrated that CPV-2c is less citopathogenic in CRFK than in primary cultures. Our study represents the first report on isolation and characterization of canine parvovirus type 2c (CPV-2c) in cell cultures from South American dogs.